[Sulglicotide in the treatment of dyspeptic patients with duodenogastric reflux].
The therapeutic efficacy of sulglicotide was tested in an open study of dyspeptic patients suffering from proven duodenogastric reflux. Twenty outpatients with non-ulcer dyspepsia and alkaline reflux demonstrated by measurement of enterogastric flux were enrolled in the study. All patients could be evaluated at the end of 8 weeks' treatment with 200 mg sulglicotide t.i.d. This treatment did not cause any change for the better of alkaline reflux but did induce marked improvement of subjective symptoms (p less than 0.05 vs baseline), giving the impression that in spite of the continued presence of the damaging agent the drug had reduced the mucosal lesion by increasing gastro-protective capacity.
Bertoldi
M
M
U.O. Chirurgia Generale, USL 20/A, Regione Toscana. S. Giovanni Valdarno.
Bigliazzi
S
S
Taddeucci
S
S
Cangioni
G
G
Psilogenis
M
M
D000328:Adult; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004341:Drug Evaluation; D004383:Duodenogastric Reflux / Q000150:complications / Q000188:drug therapy*; D004415:Dyspepsia / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D012795:Sialoglycoproteins / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors
D000897:Anti-Ulcer Agents; D012795:Sialoglycoproteins; C009354:sulglicotide
Sulglicotide nel trattamento di pazienti dispeptici affetti da reflusso duodenogastrico.